key: cord-0690541-61xnpioz
authors: Sun, Junlin; Liu, Feng; Yu, Wenqian; Fu, Dandan; Jiang, Qunying; Mo, Fengye; Wang, Xiuyuan; Shi, Tianhui; Wang, Fuan; Pang, Dai‐Wen; Liu, Xiaoqing
title: Visualization of Vaccine Dynamics with Quantum Dots for Immunotherapy
date: 2021-10-05
journal: Angew Chem Int Ed Engl
DOI: 10.1002/anie.202111093
sha: 62a750c45d13a05bf4fb09d3e92068bb09384033
doc_id: 690541
cord_uid: 61xnpioz

The direct visualization of vaccine fate is important to investigate its immunoactivation process to elucidate the detailed molecular reaction process at single‐molecular level. Yet, visualization of the spatiotemporal trafficking of vaccines remains poorly explored. Here, we show that quantum dot (QD) nanomaterials allow for monitoring vaccine dynamics and for amplified immune response. Synthetic QDs enable efficient conjugation of antigen and adjuvants to target tissues and cells, and non‐invasive imaging the trafficking dynamics to lymph nodes and cellular compartments. The nanoparticle vaccine elicits potent immune responses and anti‐tumor efficacy alone or in combination with programmed cell death protein 1 blockade. The synthetic QDs showed high fluorescence quantum yield and superior photostability, and the reliable and long‐term spatiotemporal tracking of vaccine dynamics was realized for the first time by using the synthetic QDs, providing a powerful strategy for studying immune response and evaluating vaccine efficacy.

Va ccines aim to prevent infectious diseases or treat established diseases such as cancer through manipulation of immune response. [1, 2] Over traditional treatments,v accines can orchestrate the bodyso wn immune system to eradicate cancers and pathogens for durable control and reduced recurrence. [3, 4] In vaccine development, besides the rational design of vaccine to boost immune responses, [5, 6] them onitoring of vaccine dynamics is av ery significant issue and indispensable step for immune responses considering that vaccines immunoactivation only proceeded after the efficient delivery of these vaccines to target tissues and cells. [7] Immune response is related to the vaccine formulation, the kinetics and biodistribution of vaccine exposure,c rucial to potent immunoactivation. [7, 8] Forexample,the physiological trafficking to different tissues,c ells and intracellular compartments, the cellular uptake and processing pathways,w ill influence the antigen-presenting cell (APC) activation and Tc ell priming,a nd will enhance or shape immune response in ad ifferent way. [9] Therefore,t racking vaccine dynamics and events are critical to improve mechanistic understanding, as well as assess and optimize vaccine design [10, 11] or efficacyo f immunotherapy. [12] [13] [14] Nanotechnology is proved valuable for directing immune response in vaccine development, and benefits modern vaccine design including the COVID-19 vaccine development, [1, 15] as nanoparticles and pathogens operate at similar length scale,a nd nanomaterials mimic the key structural features of microbes that are sensed by immune system, ideal for co-delivery of antigen and/or adjuvant, invoking signaling and immune response,a nd improving drug bioavailability. [16] [17] [18] Then anoparticle vaccine (nanovaccine) has additional unique advantages by targeting possible tissues or cells, enhancing intracellular delivery and antigen cross-presentation in APCs. [19] [20] [21] More importantly,b ye xploiting the inherent physicochemical properties of nanoparticles or by exploring their facile conjugation capability to label diverse molecules of interest, [22, 23] synthetic materials would encode striking features for tracking of vaccines and predicting of immune responses, [24] offering an innovative approach to visualization of vaccine dynamics.A ss uch, well-designed nanomaterials are anticipated to enable real-time tracking vaccine dynamics in vitro and in vivo for monitoring immune responses and enhanced immunotherapy;h owever, remain elusive.

Here,w er eport synthetic quantum dots (QDs) nanomaterials that enable visualization of the spatiotemporal trafficking of vaccines for immunotherapy ( Figure 1A ,B). Owing to excellent brightness,s uperior resistance to photobleaching,s mall particle size and versatile surface modifications, [25, 26] QDs are ideal labels for spatiotemporal tracking of important biological events. [27, 28] To demonstrate the noninvasive real-time visualization of dynamic immune response, we functionalize different types of core-shell semiconductor QDs that are in the red wavelength range and near-infrared (NIR) window as trackers.O ur synthetic QD materials facilely conjugate immune components,a ntigen (ovalbumin, OVA) and adjuvant (unmethylated cytosine-phosphate-gua-nine,C pG), acting as labels as well as nanocarriers.S uch nanovaccines enable optimal physical sites targeting by trafficking the nanoparticles to the draining lymph nodes and subcellular locations of lysosomes in APCs,i nducing strong APC activation and robust Tc ell priming.T hese trafficking dynamics are simultaneously visualized by the QDs-integrated nanovaccine for its high fluorescence quantum yield and superior photostability through in vitro and in vivo imaging.W ith this approach, we achieve long-term spatiotemporal tracking the in situ transmembrane procedure between nanovaccine and cellular membrane in alive cell and the intracellular transfer of vaccine into lysosome process, facilitating the study of immunoactivation at the singleparticle-level as well as the detailed molecular mechanism of Toll-like receptor 9(TLR9) activation. Besides,the synthetic QDs endow monitoring long-term spatiotemporal trafficking of the vaccine in vivo with potent immunogenicity and antitumor efficacy, providing agood guidance for appropriate vaccination interval. Af urther combination immunotherapy with anti-programmed cell death protein 1( anti-PD-1) suppresses tumors growth substantially.A sf ar as we know, it is the first time to use synthetic QDs as trackers to visualize vaccine dynamics.

QD modification involves three steps including silica coating (Experimental procedures and Figure S1 . Fourier transform infrared (FTIR) spectroscopy showed as trong absorption peak of QD@SiO 2 appeared at 3296 cm À1 ,which corresponded to the stretching vibration of -COOH relating to the surface ligands of oleic acid on QDs ( Figure 1C ). After cationic polymerization on the surface of QD@SiO 2 ,apparent absorption peaks of poly (2-(dimethylamino) ethyl methacrylate) (PDMAEMA)-modified QDs (QD@SiO 2 -Poly) appeared at 3386 cm À1 ,1 725 cm À1 and 1463 cm À1 ,a ttributed to the stretching vibration of -CONH-, C = Oa nd -C 6 H 6 ,r espectively.T hese data indicated the successful cationic PDMAEMA conjugation. In addition, comparisons via thermogravimetric analysis (TGA) showed an obviously weight loss with pyrolysis or combustion for QD@SiO 2 -Poly,c ertifying the polymerization on the surface of QDs ( Figure 1D ). Dynamic light scattering (DLS) analysis showed that the hydrodynamic diameter of QD@SiO 2 was 35.8 nm and zeta potential was À22.9 mV,w hile the hydrodynamic diameter of QD@SiO 2 -Poly increased to 63.9 nm and zeta potential reversed to + 22.5 mV ( Figure 1E ). All these results confirmed the successful fabrication of QD@SiO 2 -Poly.F inally,negatively charged OVA( isoelectric point, pI 4.7) and CpG were conjugated with positively charged QD@SiO 2 -Poly via electrostatic interaction in HEPES buffer (10 mM, pH 7.4), and various feed molar ratios of QD@SiO 2 -Poly,OVA and CpG were investigated for optimization ( Figure S4 ). To ensure both loading amount and modulate particle size for lymphatic drainage (20-100 nm), [19, 29] the feed molar ratio of QD@SiO 2 -Poly,O VA and CpG of 1/100/100 was chosen for the following experiments.A fter OVAa nd CpG conjugation, the hydrodynamic diameter of nanovaccines further elevated to 93.7 nm and zeta potential shifted to À11.5 mV ( Figure 1E ). Theamounts of OVAa nd CpG modified onto QD@SiO 2 -Poly were quantified with Bradford method and fluorescence spectra of Quasar labeled-CpG,respectively ( Figure S5 ).

We next investigated fluorescence performance and stability of the materials.T he QD@SiO 2 -Poly exhibited high quantum yield (QY,2 0.1 %, Table S1 ) and stable photoluminescence in aw ide pH range from 5t o1 0( Figure S6 ). After RAFT polymerization on QD surface or antigen/ adjuvant conjugation, QDs kept the broad absorption bands and strong and narrow emission bands ( Figure 1F ,a nd Figure S7 for NIR QD). Over 5days,the cumulative released vaccine components from the nanovaccines were less than 14 %( Figure S8 ). Methyl thiazolyl tetrazolium (MTT) and hemolysis assays showed that the synthetic QDs were nontoxic to living cells and exhibited good blood compatibility ( Figure S9 ). These results demonstrated the synthetic QDs showed high brightness,w ell photostability and biocompatibility,crucial for in vitro and in vivo applications.

There are sophisticated endocytosis pathways of nanoparticles into cells,a nd different uptake pathways not only affect uptake efficiencyo fn anovaccines,b ut also alter intracellular trafficking of nanovaccines in APCs,w hich may further affect immunoactivation of APCs. [30, 31] Therefore,westudied the endocytosis mechanism and intracellular trafficking dynamics to APCs by real-time imaging.W hen incubated with the nanovaccines,r apid cellular uptake was observed within 2h,a nd the fluorescence signal increased with the incubation time elongation, showing 8.17-fold changs at 6hcompared with that of 2h( Figure S10 ). To verify the codelivery capacity of CpG and OVA, nanovaccines were estimated by confocal fluorescence microscopy using Quasarlabeled CpG (Figure 2A ). Thenanovaccines and the Quasar-CpG were incubated with RAW264.7 cells.Little fluorescence signal was detected in cells incubated with Quasar-CpG alone, which was consistent with the facts that naked oligonucleotides are difficult to pass through the cytoplasmic membrane and prone to degradation by nucleases.T he co-localization fluorescence signals of QDs and Quasar-CpG indicated that QD@SiO 2 -Poly acted as efficient nanocarriers for delivering CpG into RAW264.7 cells.Additionally,confocal images also indicated the co-localization of Quasar-CpG and FITC-OVA in RAW264.7 cells (Figure S11 ), suggesting that QD@SiO 2 -Poly could act efficient nanocarriers for co-delivery of CpG and OVA.

Thephotostability of the synthetic QDs was evaluated by long-term imaging ( Figure S12 , Movies S1-S3), crucial factor for single particle tracking (SPT). [27, 32] Thef luorescence intensity of QDs was stable for acquiring time-series images within 5min. In comparison, the fluorescence decay of small molecules (Cy5 or FITC) was obviously observed with approximately 40 %d ecrease.T hese results demonstrated the synthetic QDs showed superior photostability for longterm tracking the vaccine dynamics in live cells compared with fluorescent small molecules.W ith the SPT technology, the nanovaccine was dynamically tracked its real-time transmembrane procedure in alive cell to elucidate the mechanism of endocytosisp rocess of nanovaccine (n = 15). RAW264.7 cells were incubated with the prechilled nanovaccines at 4 8 8C for 10 min, and then shifted to 37 8 8Cfor real-time observation (the negative and positive controls,F igure S13, S14). The dynamic transmembrane procedure of nanovaccine was tracked in aRAW 264.7 cell ( Figure 2B ). Thewhole trajectory was displayed in Figure 2C and Movie S4. Surprisingly,t he time-dependent instantaneous speed showed that the nanovaccine entered into aR AW 264.7 cell through am ultiplestaged slow-to-fast process ( Figure 2D ). Then anovaccine first confined to the cellular membrane and then rapidly transported into the cytosol. Them ovement modes of nanovaccine in two phases were also analyzed based on the mean square displacement (MSD,F igure 2E). Then anovaccine firstly experienced aslow and confined (diffusion coefficient, ca. 0.0052 mm 2 s À1 )m otion mode at the edge of cellular membranes (blue line). Subsequently,the nanovaccine moved rapidly towards the cytoplasm with am ean speed of ca. 0.31 mms À1 (red line) and ad iffusion coefficient of ca. 0.092 mm 2 s À1 .F urthermore,w hether the clathrin-mediated entry [33] was mainly involved in endocytosis of nanovaccines into RAW264.7 cells was next investigated. Cells were pretreated with chlorpromazine (CPZ) and dynasore,w hich specifically inhibit clathrin-mediated endocytosis at noncytotoxic dosages ( Figure S15 ). Confocal images and flow cytometry analysis indicated that cellular internalization of nanovaccines was drastically reduced in cells treated with both inhibitors (Figure 2F,S16) . Additionally,transferrin, aclassical marker for clathrin-mediated endocytosis,was imaged for its involvement in the nanovaccines entry into RAW264.7 cells (Figure 2G ), suggesting that 79.8 %( calculated by Pearsonsc orrelation) of the nanovaccines were co-localized with Tfn spots in the cytoplasm. These results illustrated that the nanovaccines entered into RAW264.7 cells through am ultiple-staged slow-to-fast transmembrane process via clathrin-mediated endocytosis.

Owing to the residence of TLR9 in the lysosome, [34] clathrin-mediated endocyticp athway of nanovaccines would be beneficial to potentiate the activity of CpG,t hereby enhancing the immunoactivation of RAW264.7 cells.T he interaction between nanovaccines and lysosome directly affects the efficacy of TLR9 activation. [34, 35] Therefore,t he co-localization of nanovaccines with lysosome and its transfer process into lysosome in RAW264.7 cells was next investigated. Confocal images revealed that 93.0 %( calculated by Pearsonsc orrelation) of the internalized nanovaccines colocalized with lysosome in RAW264.7 cells ( Figure 3A,B) , ensuring sufficient binding of CpG with TLR9 for immunoactivation. Furthermore,the nanovaccine was dynamically tracked its transfer process into lysosome with the whole trajectory in real-time via SPT (n = 15, Figure 3C ,D and Movie S5). Time-dependent speed suggested that the nanovaccine entered into lysosome through amultiple-staged fastto-slow process ( Figure 3E ). Then anovaccine and lysosome firstly experienced rapid and directed movement towards the same direction with am ean speed of ca. 0.78 mms À1 and ad iffusion coefficient of ca. 0.052 mm 2 s À1 (blue line in Figure 3E ,F). Then, they collided with each other in as low and confined motion mode with adiffusion coefficient of ca. 0.014 mm 2 s À1 (red line in Figure 3E ,F). These results demonstrated that the nanovaccine transfered into lysosome through amultiple-staged fast-to-slow process after clathrin-mediated endocytosis for the TLR9 activation. Our rational designed nanovaccine could provide apowerful platform for long-term spatiotemporal tracking the in situ transmembrane procedure and the intracellular transfer of vaccine into lysosome process, thus facilitating the study of immunoactivation at the singlenanoparticle-level as well as the detailed molecular mechanism of TLR9 activation. [34, 36, 37] Considering the efficient intracellular endocytosisa nd well co-localization of the materials with lysosome,t he immunoactivation of nanovaccines in RAW264.7 cells was explored, including the costimulatory molecules (CD40) expression, nitric oxide (NO) production, proinflammatory cytokine secretion, phagocytic activity and morphology of the cells.The nanovaccines induced 7.30-fold higher expression of costimulatory molecules CD40 than that of soluble CpG and OVA( Figure S17 ), indicating the activation of the RAW264.7 cell. NO is an important signaling molecule in immunomodulation, [38] and the NO production in macrophages is essential for the defense mechanisms against tumor cells. Compared with CpG + OVA, the nanovaccines induced 3.85fold higher level of NO production ( Figure S18A ), owing to efficient intracellular co-delivery of the antigen and adjuvant, and well co-localization with the lysosome for immunomodulation. Also,s ecreting proinflammatory cytokines such as tumor necrosis factor (TNF-a)a nd interleukin (IL)-6 are an important mechanism to directly kill tumor cells. [39, 40] Enzyme-linked immunosorbent assay (ELISA) analysis revealed that the nanovaccines dramatically increased secretion of TNF-a (3.72-fold) and IL-6 (20.2-fold) than that of CpG + OVA( Figure S18B,C) . Phagocytosis of pathogens by macrophages initiates the innate immune response,w hich in turn orchestrates the adaptive response.C onsistently,n eutral red uptake test indicated that cells treated with the nanovaccines Angewandte Chemie Research Articles exhibited enhanced phagocytic activity over other groups ( Figure S18D ). Additionally,m orphology change of RAW264.7 cells was used as ap otential indication of cell function and investigated by confocal images.F or inactivated RAW264.7 cells,c ells tended to be uniform and round. By contrast, once activated by the nanovaccines,c ells turned to be rougher and larger ( Figure S18E ). Lysosome escape of the antigen would contribute to priming CD8 + Tcells for potent antitumor response. [41] Thel ysosome escape capacity of nanovaccines was mimicked in vitro by the red blood cell (RBC) lysis assay,e xhibiting evident pH-dependent membrane disruptive properties ( Figure S19A ). Thel ong-term incubation of nanovaccines with RAW264.7 cells showed intense cytosolic fluorescence signal, indicating the lysosome escape of the nanovaccines ( Figure S19B ). Taken together, these results demonstrated ap otent immunoactivation of nanovaccines for its efficient intracellular delivery and lysosome escape capacity,p romising for strong immunoactivation in vivo.

Effective lymph node accumulation and durable retention of nanovaccines are vital to activate potent immunoactiva-tion. Correspondingly,i nv ivo lymphatic drainage of nanovaccines was investigated. Firstly,C 57BL/6j mice were subcutaneously (s.c.)i njected with different materials at the tail base for in vivo fluorescence imaging.T he nanovaccines showed rapid lymphatic drainage within 10 min, and exhibited stronger fluorescence intensity than the CpG and OVA mixture,i ndicating an enhanced accumulation in inguinal lymph node (ILN,F igure 4A). After 24 hp ost injection, major organs and lymph nodes from mice injected with nanovaccines were harvested for ex vivo imaging.Except for some accumulation in liver and kidney due to the metabolic clearance,t he mean radiant efficiencys howed 45.0 %o f nanovaccines accumulation in ILNs ( Figure 4B ). Consistently,exvivo images of ILNs treated with nanovaccines showed 4.24-fold higher fluorescence signal than that of CpG + OVA ( Figure 4C ). Thei ntravital spatiotemporal tracking of lymphatic drainage with NIR InP/ZnS QDs-based nanovaccines indicated that there was ad urable retention in ILNs from 0.5 hto72h( Figure 4D) . These results showed along-termed activation of immune response in vivo,w hich could guide 3days as an interval for further therapeutic antitumor study. Furthermore,cell number quantification of the resected ILNs showed increased cell number by the nanovaccines over PBS with 2.09-fold, indicating recruitment of immune cells for immunomodulation by nanovaccines ( Figure 4E ). These data on spatiotemporal tracking of lymphatic drainage demonstrated that the nanovaccines exhibited rapid accumulation and durable retention in the lymph nodes for al ong-term immune stimulus. . In vivo monitoring the nanovaccines trafficking to draining lymph nodes and the enhanced immunoactivation. A) C57BL/6j mice were s.c. injected with the CpG and OVAmixture or nanovaccines at the tail base for in vivo fluorescence imaging. The red circle referred to the ILN. CpG is labeled with Cy5. B) Ex vivo fluorescence imaging of major organs of mice injected with nanovaccinesa fter 24 h. H, Li, S, Lu, K, ALN, ILN and PLN represent heart, liver,spleen, lung, kidney,axillary lymph node, inguinal lymph node and popliteal lymph node, respectively.C )The ILNs of three different groups were harvested at 24 hpost injection for ex vivo imaging and quantification of mean fluorescence signals. n = 6, mean AE SD. D) C57BL/6j mice were s.c. injected near-infrared InP/ZnS QD-based nanovaccines at the tail base for in vivo imaging from 30 min to 72 h (left) and for calculating mean radiant efficiencyo fILN (right). The red circle referred to the ILN. n = 3, mean AE SD. E) Total cell number quantification of the resected ILNs as indicated in (C). F) C57BL/6j mice were s.c. injected at the tail base with different formulationsof QD@SiO 2 -Poly (4 mg kg À1 ,50mL), or equivalent, on day 0, 7, 14 and 21, and sacrificed for immunogenicity study on day 30. G) Flow cytometry analysis of APCs (CD40, CD86 and MHC-II expression on CD11c + cells) in ILNs. H) ELISA analysis of TNF-a (left) and IL-6 (right). I) Percentage of CD8 + CD43 + Tcells in spleen.J )Cytotoxic lymphocytes( CTL)-mediated immune responses determined by incubating B16-OVAc ells with various effector/target ratios of re-stimulated splenocytes. K) ELISA analysis of IFN-g in serum. L) Percentageo fCD8 + central memory Tcells (CD8 + CD44 + CD122 + cells) in spleen. Data in (G)-(L) were expressed as n = 4, mean AE SD. Statistical significance was calculated by one-way ANOVAwith the Bonferroni post hoc test. ***P < 0.001, **P < 0.01, *P < 0.05, ns, not significant.

Next, the immunostimulatory effects of nanovaccines were investigated in naive mice.C 57BL/6j mice were s.c. administrated at the tail base with indicated materials and sacrificed for immunogenicity study ( Figure 4F ). Flow cytometry analysis of ILNs indicated that QD@SiO 2 -Poly-CpG-OVAe xhibited higher maturation effect of APCs (1.74, 1.52 and 1.63-fold increase of CD40, CD86 and MHC-II expression on CD11c + cells,respectively) in ILNs than that of CpG + OVA( Figure 4G ), which was attributed to efficient lymphatic drainage and durable retention in the lymph nodes. Consistently,n anovaccines significantly enhanced secretion of pro-inflammatory cytokines (7.84 and 1.84-fold increased secretion of TNF-a and IL-6, respectively) than that of CpG + OVA( Figure 4H ). These results demonstrated that combination of CpG and OVAi nt he nanoparticles induced efficient co-delivery of vaccine components and significant APC maturation in vivo.APC maturation facilitates the Tcell priming,l eading to eliminating tumor cells.T hus,Tc ell response is important to evaluate the vaccine-induced immune response.Q D@SiO 2 -Poly-CpG-OVA elicited significantly more CD8 + Tc ells with 1.43 and 2.11-fold increase than that of the CpG + OVAo rQ D@SiO 2 -Poly-CpG, respectively,i ndicating the potent immunigenicity of QD@SiO 2 -Poly-CpG-OVA ( Figure 4I ,S 20A). Them ice immunized with QD@SiO 2 -Poly-CpG-OVA showed more proliferation of CD8 + Tcells in comparison with QD@SiO 2 -Poly-OVA, owing to adjuvant effect of CpG.T he antigen-specific cytotoxicity was estimated by stimulating splenocytes from immunized mice with OVAf or 60 ha nd co-incubating with B16-OVA cells.S plenocytes obtained from QD@SiO 2 -Poly-CpG-OVA treated mice exhibited higher cytotoxicity to tumor cells than other groups under the same effector/target ratio ( Figure 4J ). Furthermore,w ith the increased ratio of effector cells and target cells,t he nanovaccines showed gradually enhanced cytotoxicity of CTLs.Similarly,secretion of interferon gamma (IFN-g)was prominently enhanced with 4.23-fold after treatment by QD@SiO 2 -Poly-CpG-OVA over the CpG + OVAmixture ( Figure 4K ). Additionally,ondays 30, the mice immunized with nanovaccines showed larger fractions of central memory CD8 + Tc ells (CD8 + CD44 + CD122 + cells) compared with other groups ( Figure 4L,S 20B) , indicating durable control of Tc ell immune response.Biosafety of the nanovaccines was studied by in vivo clearance detection, hematoxylin-eosin (H&E) staining and body weight evaluation ( Figure S21-S23) , showing rapid metabolic clearance of nanovaccines in 72 hw ith well biocompatibility.Collectively,these results demonstrated that the QDs performed as spatiotemporal trackers for monitoring rapid and durable lymphatic drainage in vivo, and mediated synergistic enhancement of immunoactivation such as robust APC maturation and Tc ell responses in vivo.

To estimate whether the enhanced adaptive immune response of nanovaccines could eliminate tumor cells,invivo prophylactic study for cancer immunotherapy was carried out ( Figure 5A A) Experiments etup for prophylactictreatment. C57BL/6j mice were s.c. injected at the tail base with different formulationso fQD@SiO 2 -Poly (4 mg kg À1 ,5 0mL), or equivalent, on day 0, 7, 14 and 21. On day 30, the mice were s.c. inoculated with 4 10 4 B16-OVAc ells on the right flank. B and C) Average tumor sizes (B) and survival ratio (C) for prophylactics tudy (n = 7, mean AE SD). D) Experimentsetup for therapeutic treatment. C57BL/6j mice were s.c. inoculated with 4 10 4 B16-OVAc ells on day 0. Then the mice were s.c. injected at the tail base with QD@SiO 2 -Poly-CpG-OVA( 4mgkg À1 ,5 0mL) and on day 4, 7, 10, 13 and 16. Anti-PD-1 (10 mg) was intravenously (i.v.) administered on the same day.Eand F) Average tumor sizes (E; n = 7, mean AE SD) and representative tumor tissues (F) under these indicated treatments for therapeutics tudy.Scale bar is 1cm. Statisticals ignificance was calculated by one-way ANOVAwith the Bonferroni post hoc test.

significantly extended medium survival of the vaccinated mice.T of urther amplify the therapeutic responses and advance its practical potential, we develop ac ombination immunotherapy with vaccines and anti-PD-1 ( Figure 5D ,and average body weights of mice see Figure S26 ). Thecombination treatment exerted enhanced control of tumor growth over other groups ( Figure 5E,F and S27 ). H&E staining of tumor slices showed more necrotic/apoptotic tumor cells under the combination treatment than other groups (Figure S28A ). Thei mmunohistochemical (IHC) analysis indicated that compared with other groups,c ombination treatment exhibited higher expression CD4 + Tand CD8 + Tcells in tumor ( Figure S28B ), contributing to enhanced immune response to eliminate tumor cells.C onclusively,t hese results illustrated that nanovaccines exerted potent antitumor prophylactic and therapeutic efficacy,a nd could act synergistically with other immunotherapies,s uch as immune checkpoint blockade,a ctivating different aspects of immune response for better elimination of tumor cells.

We have demonstrated visualization of spatiotemporal trafficking of vaccine dynamics to target physiological sites with the synthetic QDs for enhanced immunity,including the efficient delivery into dendritic cells,w ell localization with lysosome,a nd targeted lymph node accumulation. The synthetic QDs showed high fluorescence quantum yield and superior photostability,e nabling reliable and long-term spatiotemporal tracking the kinetics and biodistribution of vaccine,s uch as the multiple-staged slow-to-fast transmembrane process in live cells via clathrin-mediated endocytosis and the fast-to-slow transfer of vaccine into lysosome process. Thet rafficking dynamics of nanovaccines also revealed durable retention in lymph nodes for sustained immune cell activation, robust APC maturation, and potent Tc ell responses.C orrespondingly,v accination with the nanovaccines strongly amplifies immunization in vivo,a nd the combination of nanovaccines and PD-1 blockade induces stronger immune response to combat cancer. Taken together, this work describes the spatiotemporal dynamics of nanovaccines using QD materials to help evaluate and boost immune response.S uch an anoparticle platform suggests great potentials in vaccine development and immunotherapy. Considering that more bright, stable and compatible QDs with diverse functionalities have been emerged, [42] [43] [44] these QD materials indicate additional merits for multimodal tracking of vaccines,a nd for ab etter understanding of immune response in clinical immunotherapy. [45] In addition, the QDs could conjugate with different types of therapeutic components,s uch as therapeutic nucleic acids,n eoantigens, and more, [46, 47] thus offering av ersatile platform to develop more advanced RNAvaccines for personalized therapy and combinational therapy.

Proc.N atl. Acad. Sci. USA 2020

Acceptedm anuscript online: September2 ,2 021 Version of record online

Theresearch was supported by the National Natural Science Foundation of China (21874103, 22074112, 91859123), and Fundamental Research Funds for the Central Universities (No.2042018kf1006). We thank Dr.B oT ang for his help.

Theauthors declare no conflict of interest.Keywords: imaging ·i mmune response ·n anotechnology · nanovaccines ·q uantum dots